Fedyk ER - Search Results

1

Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro.

Csizmadia V, Csizmadia E, Silverman L, Simpson C, Raczynski A, O'Brien L, Gallacher M, Cardoza K, Kadambi VJ, Fedyk ER, Alden CL. Csizmadia V, et al. Among authors: fedyk er. Vet Pathol. 2010 Mar;47(2):358-67. doi: 10.1177/0300985809358423. Epub 2010 Feb 1. Vet Pathol. 2010. PMID: 20124009

2

Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover, and induction in the neuronal cells in vitro.

Csizmadia V, Raczynski A, Csizmadia E, Fedyk ER, Rottman J, Alden CL. Csizmadia V, et al. Among authors: fedyk er. Neurotoxicology. 2008 Mar;29(2):232-43. doi: 10.1016/j.neuro.2007.11.003. Epub 2007 Nov 19. Neurotoxicology. 2008. PMID: 18155769

3

Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates.

Fedyk ER, Wyant T, Yang LL, Csizmadia V, Burke K, Yang H, Kadambi VJ. Fedyk ER, et al. Inflamm Bowel Dis. 2012 Nov;18(11):2107-19. doi: 10.1002/ibd.22940. Epub 2012 Mar 14. Inflamm Bowel Dis. 2012. PMID: 22419649

4

Predictive toxicology approaches for small molecule oncology drugs.

Maziasz T, Kadambi VJ, Silverman L, Fedyk E, Alden CL. Maziasz T, et al. Toxicol Pathol. 2010 Jan;38(1):148-64. doi: 10.1177/0192623309356448. Epub 2010 Jan 14. Toxicol Pathol. 2010. PMID: 20075108 Review.

5

Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis.

Haanstra KG, Hofman SO, Lopes Estêvão DM, Blezer EL, Bauer J, Yang LL, Wyant T, Csizmadia V, 't Hart BA, Fedyk ER. Haanstra KG, et al. Among authors: fedyk er. J Immunol. 2013 Mar 1;190(5):1961-73. doi: 10.4049/jimmunol.1202490. Epub 2013 Jan 30. J Immunol. 2013. PMID: 23365083

6

The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.

Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. Soler D, et al. Among authors: fedyk er. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. doi: 10.1124/jpet.109.153973. Epub 2009 Jun 9. J Pharmacol Exp Ther. 2009. PMID: 19509315

7

In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes.

Wyant T, Yang L, Fedyk E. Wyant T, et al. MAbs. 2013 Nov-Dec;5(6):842-50. doi: 10.4161/mabs.26392. MAbs. 2013. PMID: 24492340 Free PMC article.

8

An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.

Wyant T, Fedyk E, Abhyankar B. Wyant T, et al. J Crohns Colitis. 2016 Dec;10(12):1437-1444. doi: 10.1093/ecco-jcc/jjw092. Epub 2016 Jun 1. J Crohns Colitis. 2016. PMID: 27252400 Review.

9

A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.

Rosario M, Dirks NL, Milch C, Parikh A, Bargfrede M, Wyant T, Fedyk E, Fox I. Rosario M, et al. Clin Pharmacokinet. 2017 Nov;56(11):1287-1301. doi: 10.1007/s40262-017-0546-0. Clin Pharmacokinet. 2017. PMID: 28523450 Free PMC article. Review.

10

MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis model.

Igaki K, Komoike Y, Nakamura Y, Watanabe T, Yamasaki M, Fleming P, Yang L, Soler D, Fedyk E, Tsuchimori N. Igaki K, et al. Int Immunopharmacol. 2018 Jul;60:160-169. doi: 10.1016/j.intimp.2018.04.049. Epub 2018 May 4. Int Immunopharmacol. 2018. PMID: 29730559

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters